

List of Tables

<i>Table 1: New therapies for the treatment of RA</i>	12
<i>Table 2: List of JAK Inhibitor in clinical or in clinical development.....</i>	20
<i>Table 3: Influence of modifications at 2nd position of Pyrimidine moiety on JAK3 inhibitory activity (In-vitro).....</i>	74
<i>Table 4: Influence of modifications at 4th position of Pyrimidine moiety on JAK3 inhibitory activity (In-vitro).....</i>	99
<i>Table 5: Influence of modifications at 5th position of Pyrimidine moiety on JAK3 inhibitory activity (In-vitro).....</i>	121
<i>Table 6: Kinome Selectivity Profile of 48I.....</i>	125
<i>Table 7: In-vitro isoform selectivity of compounds against JAK1, JAK2 and TYK2 enzymes.....</i>	127
<i>Table 8: Potency and Selectivity determination of 48I in human PBMC.....</i>	129
<i>Table 9: Pharmacokinetic study parameters of 41k, 48I and Tofacitinib in C57 mice.....</i>	133
<i>Table 10: Relative organ weights (%) after 14 days repeat dose treatment with compound 48I.....</i>	137
<i>Table 11: Hematological parameters and serum chemistry of compound 48I.....</i>	138

List of Figures

<i>Figure 1: Inflammation.....</i>	1
<i>Figure 2: Classification of Chronic inflammation.....</i>	2
<i>Figure 3: Inflammatory Bowel Disease.....</i>	4
<i>Figure 4: Osteoarthritis.....</i>	5
<i>Figure 5: Irritable bowel syndrome.....</i>	6
<i>Figure 6: Asthma.....</i>	7
<i>Figure 7: Gout.....</i>	8
<i>Figure 8: Rheumatoid arthritis.....</i>	9
<i>Figure 9: Process of RA.....</i>	11
<i>Figure 10: Domain structure of JAKs.....</i>	14
<i>Figure 11: Structure of STAT protein.....</i>	15
<i>Figure 12: Cytokine signaling via JAK isoforms and their inhibitors.....</i>	16
<i>Figure 13: Mechanism of JAK-STAT pathway.....</i>	18
<i>Figure 14: Structures of Pyrimidine based JAK inhibitors.....</i>	26
<i>Figure 15: Effect of Compound 48I and Tofacitinib in AIA rat model.....</i>	135
<i>Figure 16: Effect of Compound 48I and Tofacitinib in CIA mice model.....</i>	136
<i>Figure 17: Docked pose of Cerdulatinib and 48I superimposed.....</i>	140
<i>Figure 18 Docked pose of Cerdulatinib and 48I within ATP binding site of JAK3 molecular surface (PDB ID: 5W86 @2.6Å).....</i>	141